Stock CTXR CITIUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Citius Pharmaceuticals, Inc.

Equities

CTXR

US17322U2078

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:00 03/05/2024 BST 		5-day change 1st Jan Change
0.705 USD -0.28% Intraday chart for Citius Pharmaceuticals, Inc. +6.05% -6.81%
04-26 Citius Pharmaceuticals Launches $15 Million Offering MT
04-11 Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma CI

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 21.84 57.69 296.3 176.8 108.7 127.3 - -
Enterprise Value (EV) 1 21.84 57.69 296.3 176.8 108.7 127.3 127.3 127.3
P/E ratio - - -8.83 x -5.26 x -3.11 x -3.2 x 47 x 1.31 x
Yield - - - - - - - -
Capitalization / Revenue - - - - - - 1.52 x 0.64 x
EV / Revenue - - - - - - 1.52 x 0.64 x
EV / EBITDA - - - - - - - -
EV / FCF - - -12,216,431 x - - - - -
FCF Yield - - -0% - - - - -
Price to Book - - - 1.72 x 1.2 x - - -
Nbr of stocks (in thousands) 28,836 55,476 145,979 146,130 158,858 180,523 - -
Reference price 2 0.7575 1.040 2.030 1.210 0.6844 0.7050 0.7050 0.7050
Announcement Date 16/12/19 16/12/20 15/12/21 22/12/22 29/12/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - 83.59 200
EBITDA - - - - - - - -
EBIT 1 -15.6 -17.71 -23.53 -33.32 -36.73 -36.8 8.586 100.7
Operating Margin - - - - - - 10.27% 50.34%
Earnings before Tax (EBT) 1 - - -23.05 -33.06 -31.97 -36.52 8.586 100.7
Net income 1 - - -24.51 -33.64 -33.69 -36.64 5.586 100.7
Net margin - - - - - - 6.68% 50.34%
EPS 2 - - -0.2300 -0.2300 -0.2200 -0.2200 0.0150 0.5400
Free Cash Flow - - -24.26 - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 16/12/19 16/12/20 15/12/21 22/12/22 29/12/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - - - - - - - - - - - 10.56 11.01
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -5.203 -9.259 -7.591 -8.917 -7.55 - -10.69 -8.672 -10.12 - -8.31 -8.532 -8.728 - -
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -4.961 -9.225 -7.561 -8.864 -7.415 - -10.38 -8.335 -9.8 - -8.31 -8.532 -8.728 - -
Net income 1 -4.961 -9.225 -7.561 -8.864 -7.991 -3.594 -10.53 -8.479 -11.1 - -8.31 -8.532 -8.728 - -
Net margin - - - - - - - - - - - - - - -
EPS 2 -0.0300 -0.0600 -0.0500 -0.0600 -0.0500 -0.0200 -0.0700 -0.0600 -0.0700 -0.0600 -0.0550 -0.0500 -0.0500 - -
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 15/12/21 10/02/22 12/05/22 11/08/22 22/12/22 10/02/23 12/05/23 14/08/23 29/12/23 14/02/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - -24.3 - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - 0.7000 0.5700 - - -
Cash Flow per Share - - - - - - - -
Capex - - 0.01 - - - - -
Capex / Sales - - - - - - - -
Announcement Date 16/12/19 16/12/20 15/12/21 22/12/22 29/12/23 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.705 USD
Average target price
4 USD
Spread / Average Target
+467.38%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CITIUS PHARMACEUTICALS, INC. Stock Citius Pharmaceuticals, Inc.
-6.81% 127M
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.86B
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.66B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CTXR Stock
  4. Financials Citius Pharmaceuticals, Inc.